Axcella Health (AXLA) Stock Forecast, Price Target & Predictions
AXLA Stock Forecast
Axcella Health stock forecast is as follows: an average price target of $6.00 (represents a 31.00% upside from AXLA’s last price of $4.58) and a rating consensus of 'Buy', based on 3 wall street analysts offering a 1-year stock forecast.
AXLA Price Target
The average price target for Axcella Health (AXLA) is $6.00 based on 1-year price targets from 3 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 31.00% upside from AXLA's last price of $4.58.
AXLA Analyst Ratings
According to 3 Wall Street analysts, Axcella Health's rating consensus is 'Buy'. The analyst rating breakdown for AXLA stock is 0 'Strong Buy' (0.00%), 2 'Buy' (66.67%), 1 'Hold' (33.33%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Axcella Health Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Aug 03, 2022 | - | Leerink Partners | $6.00 | $2.03 | 195.57% | 31.00% |
The latest Axcella Health stock forecast, released on Aug 03, 2022 by Leerink Partners company, set a price target of $6.00, which represents a 195.57% increase from the stock price at the time of the forecast ($2.03), and a 31.00% increase from AXLA last price ($4.58).
Axcella Health Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $4.58 | $4.58 | $4.58 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Axcella Health stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Axcella Health's last price of $4.58. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Dec 16, 2022 | SVB Leerink | Buy | Market Perform | Downgrade |
| Oct 03, 2022 | SVB Leerink | Buy | Buy | Hold |
| Sep 29, 2022 | Roth Capital | Buy | Buy | Hold |
| Aug 03, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| May 09, 2022 | Chardan Capital | Buy | Buy | Hold |
Axcella Health's last stock rating was published by SVB Leerink on Dec 16, 2022. The company Downgrade its AXLA rating from "Buy" to "Market Perform".
Axcella Health Financial Forecast
Axcella Health Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| # Analysts | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
Axcella Health's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. AXLA's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Axcella Health EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | $-3.54M |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
undefined analysts predict AXLA's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Axcella Health's previous annual EBITDA (undefined) of $NaN.
Axcella Health Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | $-3.41M |
| Avg Forecast | $113.58M | $98.93M | $116.17M | $153.89M | $-92.11M | $87.86M |
| High Forecast | $113.58M | $98.93M | $116.17M | $153.89M | $-92.11M | $87.86M |
| Low Forecast | $113.58M | $98.93M | $116.17M | $153.89M | $-92.11M | $87.86M |
| Surprise % | - | - | - | - | - | -0.04% |
Axcella Health's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. AXLA's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Axcella Health SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | $2.32M |
| Avg Forecast | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - |
Axcella Health's average Quarter SG&A projection for Sep 23 is -, based on 0 Wall Street analysts, with a range of - to -. The forecast indicates a -100.00% fall compared to AXLA last annual SG&A of $2.32M (Jun 23).
Axcella Health EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - |
| Avg Forecast | $1.54 | $1.34 | $1.58 | $2.09 | $-1.25 | $1.19 |
| High Forecast | $1.54 | $1.34 | $1.58 | $2.09 | $-1.25 | $1.19 |
| Low Forecast | $1.54 | $1.34 | $1.58 | $2.09 | $-1.25 | $1.19 |
| Surprise % | - | - | - | - | - | - |
According to undefined Wall Street analysts, Axcella Health's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to AXLA previous annual EPS of $NaN (undefined).
Axcella Health Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AKTX | Akari Therapeutics | $2.78 | $12.00K | 431554.68% | - |
| CTMX | CytomX Therapeutics | $1.05 | $5.77 | 449.52% | Buy |
| NUVB | Nuvation Bio | $2.30 | $6.75 | 193.48% | Buy |
| TIL | Instil Bio | $28.78 | $78.25 | 171.89% | Hold |
| KZR | Kezar Life Sciences | $7.21 | $17.50 | 142.72% | Buy |
| ASMB | Assembly Biosciences | $16.89 | $35.50 | 110.18% | Buy |
| AXLA | Axcella Health | $4.58 | $6.00 | 31.00% | Buy |
AXLA Forecast FAQ
Is Axcella Health a good buy?
Yes, according to 3 Wall Street analysts, Axcella Health (AXLA) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 66.67% of AXLA's total ratings.
What is AXLA's price target?
Axcella Health (AXLA) average price target is $6 with a range of $6 to $6, implying a 31.00% from its last price of $4.58. The data is based on 3 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Axcella Health stock go up soon?
According to Wall Street analysts' prediction for AXLA stock, the company can go up by 31.00% (from the last price of $4.58 to the average price target of $6), up by 31.00% based on the highest stock price target, and up by 31.00% based on the lowest stock price target.
Can Axcella Health stock reach $7?
AXLA's average twelve months analyst stock price target of $6 does not support the claim that Axcella Health can reach $7 in the near future.
What are Axcella Health's analysts' financial forecasts?
AXLA's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $149.64M (high $149.64M, low $149.64M), average SG&A $0 (high $0, low $0), and average EPS is $2.03 (high $2.03, low $2.03).